FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2609740091> ?p ?o ?g. }

• W2609740091 endingPage "48" @default.
• W2609740091 startingPage "39" @default.
• W2609740091 abstract "Objective: Our previous findings suggested that the suppression of tumor necrosis factoralpha (TNF-α)-induced matrix metalloproteinase (MMP)-9 production by the biscoclaurine alkaloid cepharanthine could prevent the destruction of the acinar structure in the salivary glands of murine Sjogren's syndrome. Here, we examined the effect of cepharanthine on the salivary secretion in primary Sjogren's syndrome (pSS) patients.Methods: In this single-center, open-label pilot study, 29 patients with pSS (28 women, 1 man) received 6 mg/day orally cepharanthine for 12 months. Standard clinical assessments and stimulated salivary flow were examined at baseline and each month for 12 months in all 29 patients. In eight of the patients, inflammatory lesions in the salivary glands were histologically investigated before and after the cepharanthine treatment. We analyzed the expressions of p65, phosphorylated IκB-α, MMP-9, and type IV collagen immunohistochemically.Results: All patients completed the study without any adverse events. A significant increase in salivary flow was observed after the cepharanthine treatment compared to baseline. The serological analysis revealed that the 14 patients with an anti-Sjogren's-syndrome-related antigen A (anti-SSA/Ro) antibody value that was either negative or 64 U/ml did not. The immunohistochemical analysis demonstrated that although p65, phosphorylated IκB-α, and MMP-9 were more strongly stained in the acinar cells of the patients at baseline compared to the staining at the completion of cepharanthine treatment, the continuity of type IV collagen was observed following the cepharanthine treatment. These results indicate that cepharanthine could inhibit the phosphorylation of IκB-α, followed by the prevention of MMP-9 activation and the stabilization of type IV collagen.Conclusions: Our findings suggest that cepharanthine could be a promising agent for improving salivary secretion in pSS patients." @default.
• W2609740091 created "2017-05-05" @default.
• W2609740091 creator A5021947374 @default.
• W2609740091 creator A5054108206 @default.
• W2609740091 creator A5066523746 @default.
• W2609740091 creator A5077883017 @default.
• W2609740091 date "2017-04-04" @default.
• W2609740091 modified "2023-09-23" @default.
• W2609740091 title "Treatment with the Biscoclaurine Alkaloid Cepharanthine Significantly Increases Salivary Secretion in Primary Sjögren's Syndrome Patients" @default.
• W2609740091 cites W1573411722 @default.
• W2609740091 cites W1596190107 @default.
• W2609740091 cites W1827917779 @default.
• W2609740091 cites W1902015763 @default.
• W2609740091 cites W1981393628 @default.
• W2609740091 cites W1985807346 @default.
• W2609740091 cites W1986628830 @default.
• W2609740091 cites W1994724205 @default.
• W2609740091 cites W2005367309 @default.
• W2609740091 cites W2005621871 @default.
• W2609740091 cites W2007451263 @default.
• W2609740091 cites W2011468496 @default.
• W2609740091 cites W2024334721 @default.
• W2609740091 cites W2028071251 @default.
• W2609740091 cites W2038554369 @default.
• W2609740091 cites W2040113869 @default.
• W2609740091 cites W2059983531 @default.
• W2609740091 cites W2076072424 @default.
• W2609740091 cites W2076642084 @default.
• W2609740091 cites W2080234145 @default.
• W2609740091 cites W2085414281 @default.
• W2609740091 cites W2090497409 @default.
• W2609740091 cites W2121164372 @default.
• W2609740091 cites W2128394628 @default.
• W2609740091 cites W2128488331 @default.
• W2609740091 cites W2132513869 @default.
• W2609740091 cites W2142664470 @default.
• W2609740091 cites W2148726393 @default.
• W2609740091 cites W2345865822 @default.
• W2609740091 cites W2430147249 @default.
• W2609740091 cites W2041244673 @default.
• W2609740091 doi "https://doi.org/10.20738/johb.29.2_39" @default.
• W2609740091 hasPublicationYear "2017" @default.
• W2609740091 type Work @default.
• W2609740091 sameAs 2609740091 @default.
• W2609740091 citedByCount "0" @default.
• W2609740091 crossrefType "journal-article" @default.
• W2609740091 hasAuthorship W2609740091A5021947374 @default.
• W2609740091 hasAuthorship W2609740091A5054108206 @default.
• W2609740091 hasAuthorship W2609740091A5066523746 @default.
• W2609740091 hasAuthorship W2609740091A5077883017 @default.
• W2609740091 hasConcept C126322002 @default.
• W2609740091 hasConcept C134018914 @default.
• W2609740091 hasConcept C142724271 @default.
• W2609740091 hasConcept C159654299 @default.
• W2609740091 hasConcept C197934379 @default.
• W2609740091 hasConcept C203014093 @default.
• W2609740091 hasConcept C204232928 @default.
• W2609740091 hasConcept C2778937882 @default.
• W2609740091 hasConcept C45189115 @default.
• W2609740091 hasConcept C71924100 @default.
• W2609740091 hasConcept C90924648 @default.
• W2609740091 hasConcept C98274493 @default.
• W2609740091 hasConceptScore W2609740091C126322002 @default.
• W2609740091 hasConceptScore W2609740091C134018914 @default.
• W2609740091 hasConceptScore W2609740091C142724271 @default.
• W2609740091 hasConceptScore W2609740091C159654299 @default.
• W2609740091 hasConceptScore W2609740091C197934379 @default.
• W2609740091 hasConceptScore W2609740091C203014093 @default.
• W2609740091 hasConceptScore W2609740091C204232928 @default.
• W2609740091 hasConceptScore W2609740091C2778937882 @default.
• W2609740091 hasConceptScore W2609740091C45189115 @default.
• W2609740091 hasConceptScore W2609740091C71924100 @default.
• W2609740091 hasConceptScore W2609740091C90924648 @default.
• W2609740091 hasConceptScore W2609740091C98274493 @default.
• W2609740091 hasIssue "2" @default.
• W2609740091 hasLocation W26097400911 @default.
• W2609740091 hasOpenAccess W2609740091 @default.
• W2609740091 hasPrimaryLocation W26097400911 @default.
• W2609740091 hasRelatedWork W1502840565 @default.
• W2609740091 hasRelatedWork W1902015763 @default.
• W2609740091 hasRelatedWork W1976496585 @default.
• W2609740091 hasRelatedWork W2027646689 @default.
• W2609740091 hasRelatedWork W2055400548 @default.
• W2609740091 hasRelatedWork W2109572131 @default.
• W2609740091 hasRelatedWork W2138770202 @default.
• W2609740091 hasRelatedWork W2148726393 @default.
• W2609740091 hasRelatedWork W2324053510 @default.
• W2609740091 hasRelatedWork W2551823973 @default.
• W2609740091 hasRelatedWork W2589943967 @default.
• W2609740091 hasRelatedWork W2939290887 @default.
• W2609740091 hasRelatedWork W2968519166 @default.
• W2609740091 hasRelatedWork W3004863251 @default.
• W2609740091 hasRelatedWork W3026491706 @default.
• W2609740091 hasRelatedWork W3031712162 @default.
• W2609740091 hasRelatedWork W3033893894 @default.
• W2609740091 hasRelatedWork W3080953187 @default.
• W2609740091 hasRelatedWork W3113579495 @default.
• W2609740091 hasRelatedWork W3158896462 @default.

• next